文献速递细菌感染、耐药与抗菌药物医院感染防控

癌症及免疫抑制患者中的肠致病性大肠埃希菌感染

Enteropathogenic Escherichia coli Infection in Cancer and Immunosuppressed Patients.
PubMed 文献 · Clin Infect Dis · 2021-01-01

本研究纳入77例癌症或免疫抑制合并腹泻且粪便Filmarray检出EPEC的成人患者、25例病原阴性腹泻患者及21例健康成人,采用qRT-PCR定量EPEC基因eaeA和lifA/efa-1并分析菌株特征。EPEC患者更常为社区获得性腹泻,免疫抑制者细菌负荷更高,92%以EPEC为唯一病原者对抗菌治疗有应答,但耐药常见且可延误癌症治疗。

要点

  • 免疫抑制癌症患者EPEC腹泻细菌负荷高,应重视其致病性。
  • EPEC为唯一病原时抗菌治疗应答率92%,但耐药常见。
  • EPEC感染可导致13%患者癌症治疗延迟。

核心结论

  • 免疫抑制癌症患者EPEC腹泻携带高负荷耐药菌株,在人类肠道类器官中呈现新黏附模式,并干扰癌症治疗。

研究设计与样本

  • 研究纳入77例粪便Filmarray检出EPEC的成人癌症或免疫抑制腹泻患者、25例病原阴性腹泻患者和21例无腹泻健康成人。
  • 采用qRT-PCR定量EPEC基因eaeA和lifA/efa-1,并分析菌株毒力因子及对人肠道类器官的黏附。

主要发现

  • 48例EPEC为唯一病原的患者中44例(92%)对抗菌治疗有应答。

临床怎么用

  • 对免疫抑制癌症合并腹泻患者,应识别EPEC并考虑定量检测以区分定植与感染。
  • 治疗EPEC腹泻时需考虑耐药风险,并根据药敏结果选择抗菌药物。
  • EPEC感染可能延误癌症治疗,需及时管理以保障抗肿瘤治疗连续性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of enteropathogenic Escherichia coli (EPEC) as a cause of diarrhea in cancer and immunocompromised patients is controversial. Quantitation of fecal bacterial loads has been proposed as a method to differentiate colonized from truly infected patients. METHODS: We studied 77 adult cancer and immunosuppressed patients with diarrhea and EPEC identified in stools by FilmArray, 25 patients with pathogen-negative diarrhea, and 21 healthy adults without diarrhea. Stools were studied by quantitative polymerase chain reaction (qRT-PCR) for EPEC genes eaeA and lifA/efa-1 and strains characterized for virulence factors and adherence to human intestinal enteroids (HIEs). RESULTS: Patients with EPEC were more likely to have community-acquired diarrhea (odds ratio, 3.82 [95% confidence interval, 1.5-10.0]; P = .008) compared with pathogen-negative cases. Although EPEC was identified in 3 of 21 (14%) healthy subjects by qPCR, the bacterial burden was low compared to patients with diarrhea (≤55 vs median, 6 × 104 bacteria/mg stool; P < .001). Among EPEC patients, the bacterial burden was higher in those who were immunosuppressed (median, 6.7 × 103 vs 55 bacteria/mg; P < .001) and those with fecal lifA/ifa-1 (median, 5 × 104 vs 120 bacteria/mg; P = .015). Response to antimicrobial therapy was seen in 44 of 48 (92%) patients with EPEC as the sole pathogen. Antimicrobial resistance was common and strains exhibited distinct patterns of adherence with variable cytotoxicity when studied in HIEs. Cancer care was delayed in 13% of patients. CONCLUSIONS: Immunosuppressed cancer patients with EPEC-associated diarrhea carry high burden of EPEC with strains that are resistant to antibiotics, exhibit novel patterns of adherence when studied in HIEs, and interfere with cancer care.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Olvera A, Carter H, Rajan A, et al. Enteropathogenic Escherichia coli Infection in Cancer and Immunosuppressed Patients. Clin Infect Dis. 2021. PMID: 32930708. doi:10.1093/cid/ciaa1394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。